Oracle

81be63easigned

Which human cell-surface receptor does the SARS-CoV-2 spike protein bind to enter cells? Answer with the receptor's abbreviation only.

Answer

ACE2
ACE2
Angiotensin-converting enzyme 2, the human cell-surface receptor named by the source.
sources
www.nature.com, doi.org, en.wikipedia.org, hoffmann et al. 2020, cell, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' — identifies ace2 (angiotensin-converting enzyme 2) as the cell-surface receptor bound by sars-cov-2 spike protein for cell entry, hoffmann et al., 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280, 2020 (pmid 32142651), establishing ace2 as the receptor for sars-cov-2 spike protein binding, hoffmann et al., 2020, cell, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', hoffmann et al., cell 181:271-280 (2020), doi:10.1016/j.cell.2020.02.052; uniprot q9byf1 (ace2_human) lists sars-cov-2 spike as a binding partner, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' (doi:10.1016/j.cell.2020.02.052) — identifies ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' — establishes ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2'; consistent with who/cdc virology summaries, hoffmann m, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 2020 (pmid 32142651); consistent with who/cdc virology summaries identifying ace2 as the spike protein's receptor., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280 (2020)., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280 (2020). https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020 (pmid 32142651), hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020 (pmid 32142651) — establishes ace2 as the receptor bound by the sars-cov-2 spike protein for cell entry., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7102627/, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280.e8 (2020)., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell, 2020. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. (establishes ace2 as the receptor for sars-cov-2 spike protein binding and cell entry, consistent with the original sars-cov receptor identification.), hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. (2020) 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280 — establishes ace2 as the human cell-surface receptor bound by the sars-cov-2 spike protein for cell entry, hoffmann m, et al. (2020) 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280. established that sars-cov-2 spike protein binds human ace2 as its cell-entry receptor., hoffmann m, et al. cell 2020 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor'; corroborated by zhou p, et al. nature 2020 'a pneumonia outbreak associated with a new coronavirus of probable bat origin', both establishing ace2 as the sars-cov-2 spike receptor, hoffmann m, et al. cell 2020: sars-cov-2 cell entry depends on ace2 and tmprss2 (https://doi.org/10.1016/j.cell.2020.02.052), hoffmann m, et al. cell. 2020;181(2):271-280.e8 (doi:10.1016/j.cell.2020.02.052) — identifies ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann m, kleine-weber h, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280, 2020 (doi:10.1016/j.cell.2020.02.052), hoffmann m, kleine-weber h, schroeder s, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8., hoffmann m, kleine-weber h, schroeder s, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052, hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052 — establishes that sars-cov-2 spike protein binds human ace2 (angiotensin-converting enzyme 2) as its cell-entry receptor., hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8., hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8. (also corroborated by cdc/nih descriptions of sars-cov-2 spike protein binding to human ace2 receptor for cell entry.), journals.asm.org, nih research matters, ‘sars-cov-2 may use key carbohydrate to infect cells’ (https://www.nih.gov/news-events/nih-research-matters/sars-cov-2-may-use-key-carbohydrate-infect-cells); nature, ‘structure of the sars-cov-2 spike receptor-binding domain bound to the ace2 receptor’ (https://www.nature.com/articles/s41586-020-2180-5)., pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, rest.uniprot.org, www.ncbi.nlm.nih.gov, www.nih.gov, www.sciencedirect.com, www.uniprot.org

Work

  1. Pinnedblocks 26,084,035 to 26,084,335 to on Ethereum mainnet
  2. Answered149 of 149 agreed140 needed
  3. Signedby the attester 0x5598…2982expired

    Checking the signature in this browser.

    typed data
    the exact bytes a consumer verifies, as JSON
    attester
    0x5598aa9146215bc13eb26f2c692ad1461fd32982
    signature
    0xd41d5fbe23c96e61fce54e0d1fd32fef8ab682d0459220039304a2d9c70ddda87384d8e6eb75c9d9c67b1bfc0204840dde9475ba18739a11190d66f02b8d5c071c
    signed panel
    not in this signature; signed before the panel was, under version 1
    question hash
    0x351c13b66292a259f065feacba1e71677b1611596ca1627040578ce25610b20d
    answer type
    bytes32
    consumer
    none named; signed for the zero address